Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Geyer

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Cancers|January 21, 2022
The Alliance AMBUSH Trial: Rationale and DesignAnita Mahajan, Helen Shih, Marta Penas-Prado, et al.
The Lancet. Oncology|March 29, 2023
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials ConferenceRifaquat Rahman, Mei-Yin C Polley, Laura Alder, et al.
Investigational New Drugs|August 8, 2018
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)Paul Monk, Glenn Liu, Walter M Stadler, et al.
Diabetes Care|September 2, 2017
Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention TrialsBrandon M Nathan, David Boulware, Susan Geyer, et al.
The Pharmacogenomics Journal|April 28, 2022
KDR genetic predictor of toxicities induced by sorafenib and regorafenibJulia C F Quintanilha, Susan Geyer, Amy S Etheridge, et al.
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Oncotarget|April 23, 2016
Long term effects of radiation exposure on telomere lengths of leukocytes and its associated biomarkers among atomic-bomb survivorsAna Lustig, Ivo Shterev, Susan Geyer, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Diabetes Care|March 6, 2020
Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236Emily K Sims, Susan Geyer, Suzanne Bennett Johnson, et al.
Diabetes Care|September 28, 2019
Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to PreventionEmily K Sims, Susan Geyer, Suzanne Bennett Johnson, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Cancers|January 21, 2022
The Alliance AMBUSH Trial: Rationale and DesignAnita Mahajan, Helen Shih, Marta Penas-Prado, et al.
The Lancet. Oncology|March 29, 2023
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials ConferenceRifaquat Rahman, Mei-Yin C Polley, Laura Alder, et al.
Investigational New Drugs|August 8, 2018
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)Paul Monk, Glenn Liu, Walter M Stadler, et al.
Diabetes Care|September 2, 2017
Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention TrialsBrandon M Nathan, David Boulware, Susan Geyer, et al.
The Pharmacogenomics Journal|April 28, 2022
KDR genetic predictor of toxicities induced by sorafenib and regorafenibJulia C F Quintanilha, Susan Geyer, Amy S Etheridge, et al.
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Oncotarget|April 23, 2016
Long term effects of radiation exposure on telomere lengths of leukocytes and its associated biomarkers among atomic-bomb survivorsAna Lustig, Ivo Shterev, Susan Geyer, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Diabetes Care|March 6, 2020
Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236Emily K Sims, Susan Geyer, Suzanne Bennett Johnson, et al.
Diabetes Care|September 28, 2019
Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to PreventionEmily K Sims, Susan Geyer, Suzanne Bennett Johnson, et al.
Pageof 12